JAN 09, 2018 6:17 AM PST

Something Else for Beta Blockers to Do: Treat Melanoma

WRITTEN BY: Kara Marker

A drug used to lower blood pressure and prevent heart attacks could also be used to treat melanoma. From Penn State, researchers are studying how a specific type of beta blocker - widely available and approved by the FDA - can improve the effectiveness of cancer immunotherapy for melanoma patients whose cancer has spread to different tissues in the body.

Credit: Penn State / © iStock Photo / digicomphoto

Beta blockers reduce blood pressure by opening up blood vessels to improve blood flow and prevent heart attacks by inhibiting the effects of epinephrine, a hormone also called adrenaline. Pan beta blockers are commonly known to be safe, which means that they could be more quickly applied to melanoma patients than a newly developed drug. In theory, beta blockers are able to lower stress to empower the immune system to fight cancer on its own.

"Most patients are either prescribed beta-1 selective blockers or are not taking beta blockers at all,” explained Dr. Todd Schell. “This means there's a large population of patients who may be eligible to take pan beta blockers while being treated with immunotherapy.”

Metastatic melanoma patients receiving immunotherapy may have the best chance at living longer, although even with the treatment the response rates are low - less than 35 percent. “How can we make these treatments better?” asked Penn State’s Dr. Joseph Drabick.

"Beta blockers slow your heart rhythm, but they can also affect immune cells and improve immune function," Schell said. "We wanted to see if there would be a correlation between the beta blockers patients were taking for another condition and their response to immunotherapy.”

The new Penn State study involved giving beta blockers to melanoma patients receiving cancer immunotherapy as opposed to just immunotherapy. Of 195 metastatic melanoma patients being treated with immunotherapy, 62 were also taking beta blockers. Schell, Drabick, and the other researchers compared survival between patients taking two different kinds of beta blockers, beta 1-selective and pan beta blockers, and patients taking no beta blockers at all.

The results showed that patients taking pan beta blockers were significantly more likely to survive (70 percent alive after five years of immunotherapy) than patients taking beta 1-selective beta blockers or no beta blockers at all (25 percent). Researchers completed virtually the same study again, this time in mice with melanoma. Like the human trial, the mice were receiving immunotherapy with or without additional treatment of pan beta blockers. Immunotherapy plus pan beta blockers delayed tumor growth and increased survival.

“We saw that for patients taking pan beta blockers, there was a dramatic improvement in survival, and we were able to duplicate these findings in mice and see the exact same phenomenon,” Drabick explained.

Going forward, the Penn State researchers will continue their study on using beta blockers to improve immunotherapy to potentially treat a variety of cancers.

The present study was published in the journal OncoImmunology.

Sources: MayoClinic, Penn State

About the Author
I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 01, 2022
Cancer
Pre-clinical Study Describes a Strategy to Improve Adoptive Cell Therapy
SEP 01, 2022
Pre-clinical Study Describes a Strategy to Improve Adoptive Cell Therapy
Immune cells, known as T cells (also called T lymphocytes), play a vital role in the anti-tumor immune response.  T ...
SEP 07, 2022
Cell & Molecular Biology
Sequencing Living Cells, Individually, Without Killing Them
SEP 07, 2022
Sequencing Living Cells, Individually, Without Killing Them
When genes in a cell are active, they are transcribed into messenger RNA (mRNA) molecules. So researchers can take a sna ...
OCT 12, 2022
Plants & Animals
Mediterranean Diet Improves Immunotherapy Response in Advanced Melanoma Patients
OCT 12, 2022
Mediterranean Diet Improves Immunotherapy Response in Advanced Melanoma Patients
The Mediterranean diet has been popularized in recent years for its wide-ranging health benefits. Among the many health ...
OCT 19, 2022
Plants & Animals
Prunes Help Protect Bone Health from Inflammation in Menopausal Women
OCT 19, 2022
Prunes Help Protect Bone Health from Inflammation in Menopausal Women
Conditions like osteoporosis affect an estimated 10 million adults over 50 years of age, with a much higher incidence ra ...
OCT 26, 2022
Health & Medicine
Getting Less than Five Hours of Sleep a Night Linked to Multiple Diseases
OCT 26, 2022
Getting Less than Five Hours of Sleep a Night Linked to Multiple Diseases
In 1985, the Whitehall II cohort study began collecting data on 10,308 participants employed in the London offices of th ...
OCT 31, 2022
Genetics & Genomics
Ancient Viral DNA in Our Genome Has a Protective Function
OCT 31, 2022
Ancient Viral DNA in Our Genome Has a Protective Function
There is viral DNA in the human genome, and each instance traces back to an ancestor who was infected with a retrovirus. ...
Loading Comments...